Mass spectrometry (MS)-based MHC immunopeptidome profiling offers a direct approach to validate neoantigen presentation by isolating peptide–MHC complexes from tumor tissues and sequencing the bound peptides. The gene discussed is HLA-C; the disease is neoplasm.